2008

01/29//2008
Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

2007

06/11/2007
Viventia Biotech Initiates Patient Treatment For Phase I Trial Of VB6-845 Anti-Cancer Antibody

05/24/2007
Viventia Biotech Reports Final Vicinium™ Phase I/II Bladder Cancer Data At The American Urological Association Annual Meeting

04/18/2007
Viventia Biotech Reports Synergistic Effect Of Its Proxinium™ Antibody In Combination With Chemotherapy And Radiation

04/18/2007
Viventia Biotech Generates Novel Human Anti-Cancer Antibody, Vb1-050, And Identifies Its Novel Target

04/03/2007
Viventia Biotech Initiates Patient Treatment For Vicinium™ Phase II Bladder Cancer Trial

02/14/2007
Viventia Biotech Provides Update On Cancer Antibody Clinical Development Programs - Pivotal Phase Iii Target Trial On Track To Deliver Interim Data In Late-2007 -


2005

12/23/2005
Viventia announces voting results of the shareholders meeting and the closing of transaction to become a private company

11/25/2005
Viventia announces $10.6 Million Interim Financing

11/14/2005
Viventia announces transaction to become a private company

11/10/2005
Viventia receives fast track designation from the FDA for Proxinium™ in Head and Neck Cancer

10/06/2005
Viventia provides update of Vicinium™ Clinical Program

10/05/2005
Viventia receives Health Canada clearance to initiate phase II cancer trial for Proxinium™

09/16/2005
Viventia receives FDA Clearance to initiate Phase II CANCER trial for Proxinium™

06/16/2005
Viventia forms Head & Neck Cancer Clinical Advisory Board

06/1/2005
Viventia's Proxinium™ Receives EU Orphan Drug Designation

05/12/2005
Viventia to Present Proxinium™ Posters at ASCO

05/11/2005
Viventia Biotech Reports First Quarter 2005 Results

05/03/2005
Viventia to Present at the Rodman & Renshaw Techvest 2nd Annual Healthcare Conference

04/18/2005
Viventia Biotech Inc. Four Posters at American Association of Cancer Research Annual Meeting

04/07/2005
Viventia Biotech Inc. Amend's Proxinium™ Bladder Cancer Trial to include Phase II arm

03/31/2005
Viventia Biotech Inc. to seek U.S. listing for its Common Shares

03/29/2005
Viventia Biotech Inc. reports positive Head & Neck Cancer results

03/23/2005
Viventia Biotech Inc. announces $4.6 Million Interim Financing

03/23/2005
Viventia Biotech Inc. reports 2004 year-end results

02/3/2005
U.S. Food and Drug Administration Grants Viventia Biotech
Orphan Drug Designation for Proxinium™

02/2/2005
Affitech and Viventia Biotech Announce Cancer Research Milestone Achievements

01/25/2005
Viventia Completes Enrolment of Second PROXINIUM™ Clinical Trial


2004

12/21/2004
Viventia Biotech Inc. announces loan approval

11/17/2004
Viventia Biotech Inc. enhances Bladder Cancer program

11/12/2004
Viventia Biotech Inc. Reports Third Quarter 2004 Financial Results

11/03/2004
Viventia Biotech Inc. announces closing of private placement

10/27/2004
Proxinium™ demonstrates positive clinical responses in Head and Neck Cancer clinical trial

10/25/2004
Viventia Biotech Inc to present Preliminary Clinical Trial Results at Rodman & Renshaw Techvest Conference

10/20/2004
Viventia Biotech Inc Announces Results of Special Meeting of Shareholders

10/14/2004
Viventia Biotech Inc. files Orphan drug application with FDA for PROXINIUM™
in Head and Neck Cancer

10/06/2004
Viventia Biotech Inc. to present at three Major Health Care Conferences

09/07/2004
Viventia Biotech Inc. Obtains Interim Funding

08/20/2004
Viventia Biotech Inc. announces Special Meeting

08/19/2004
Viventia Biotech receives approval from Health Canada to investigate Proxinium™ in Bladder Cancer

08/18/2004
Viventia Biotech Inc. and ACCEPTYS, INC. Announces option agreement for Human Anti-Cancer Monoclonal Antibodie.

08/16/2004
Viventia Biotech Inc. provides Financing Updates

08/16/2004
Viventia Biotech reports Second Quarter 2004 Financial Results

07/19/2004
Viventia Biotech Inc. Announces Filing of Second Amended and Restated Preliminary...

06/21/2004
Viventia Biotech Inc. Announces results of Annual Meeting of Shareholders

06/8/2004
EvoGenix to partner with Viventia to create second generation Armed Antibodies™

06/8/2004
Viventia Biotech Inc. Announces filing of Amended and Restated Preliminary prospectus.

06/7/2004
Viventia Biotech Inc. expands Clinical Program in Head and Neck Cancer

05/27/2004
Viventia Biotech Inc. Obtains Interim Funding

05/10/2004
Viventia Biotech Inc Announces Results of Special Meeting of Shareholders

04/29/2004
Viventia Biotech Inc. Obtains Interim Funding

04/20/2004
Viventia Biotech Inc. Obtains Interim Funding

04/14/2004
Viventia Biotech Inc. files Preliminary Prospectus

04/14/2004
Viventia Biotech Reports Results For Year-Ended December 31, 2003

04/05/2004
Viventia Biotech Obtains Interim Funding

03/16/2004
Viventia and Esbatech Enter Collaboration To Enhance Antibodies

03/09/2004
Viventia Biotech Announces Special Meeting

03/08/2004
Viventia Biotech Obtains Interim Funding

02/17/2004
Viventia Biotech Inc. Adds Strength and Experience To Its Senior...

01/28/2004
Viventia Biotech Inc. Corporate Update

01/08/2004
Viventia Biotech Announces Dr. Nick Glover...



Click here for a list of recent archived press releases